News Search Results
Aug 06, 2024, 16:01 ET HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Aug 06, 2024, 16:01 ET AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Aug 06, 2024, 14:30 ET Total Reflection X-Ray Fluorescence Spectrometer Market size is set to grow by USD 1.32 billion from 2024-2028, Rising focus on drug discovery and development to boost the market growth, Technavio
vaccine demand due to immunization awareness, TRXRF becomes indispensable for vaccine development. Significant investments in the pharmaceutical and biotechnology industries by governments worldwide, totaling approximately USD120 billion in 2021, will fuel market growth during
More news about: Technavio
Aug 06, 2024, 11:08 ET YouthBio Therapeutics Announces Significant Results from Joint Study with Dr. Ocampo Demonstrating Amelioration of Age-Related Cognitive Decline
Aug. 6, 2024 /PRNewswire/ -- YouthBio Therapeutics (YouthBio), a pioneering longevity biotechnology company developing partial reprogramming-based gene therapies, today announced significant research results from its collaboration with Dr.
More news about: YouthBio Therapeutics Inc.
Aug 06, 2024, 10:30 ET Single-Cell Analysis Market worth $6.9 billion by 2029 driven by Technological Advancements | MarketsandMarkets™
single-cell analysis market is driven by rising cancer and immunological disorders, advancements in technology, increased focus on stem cell research and biotechnology, and the development of personalized medicine. Technological innovations, such as 10X Genomics' GEM-X and Standard BioTools' Hyperion XTi Imaging
More news about: MarketsandMarkets
Aug 06, 2024, 10:30 ET MERCALIS AND TRIANGLE INSIGHTS GROUP ANNOUNCE SENIOR LEADERSHIP APPOINTMENTS
/PRNewswire/ -- Triangle Insights Group (Triangle), a premier strategy consulting firm that advises senior life science leaders in the pharmaceutical, biotechnology, and related industries on questions related to market access, commercial strategy, product launch, and corporate strategy, today announced two
More news about: Mercalis
Aug 06, 2024, 10:01 ET Multiplex Assays Market to be Worth $6.80 Billion by 2031 - Exclusive Report by Meticulous Research®
other end users. The pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR during the forecast period. The highest CAGR of the segment is attributed to increasing R&D investments by pharmaceutical & biotechnology companies, the widespread utilization of multiplex
More news about: Meticulous Market Research Pvt. Ltd.
Aug 06, 2024, 09:05 ET TWO BEAR CAPITAL EXPANDS TEAM OF EXPERTS DURING PERIOD OF RAPID GROWTH
Bridget Martell MA, MD and Jeff Miller Join As Operating Partners Supporting the Biotechnology and Enterprise Portfolio Companies, Respectively Tim Veil Joins As Principal Focused on New Technology; Kevin Day and Jennifer
More news about: Two Bear Capital
Aug 06, 2024, 08:08 ET Artax Biopharma Raises $8 Million Ahead of Phase 2a Data Expected in Q4-2024
Mass., Aug. 6, 2024 /PRNewswire/ -- Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces the closure of an $8 million
More news about: Artax Biopharma
Aug 06, 2024, 08:01 ET NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has signed a joint research agreement, together with Dong-A ST
More news about: NeuroBo Pharmaceuticals, Inc.
Aug 06, 2024, 08:00 ET Shinobi Therapeutics Secures $59M Grant from the Japanese Agency for Medical Research and Development
Japan, Aug. 6, 2024 /PRNewswire/ -- Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS cell therapies, today announced that it has been awarded up to $59M
More news about: Shinobi Therapeutics
Aug 06, 2024, 08:00 ET NeuroTherapia Raises $12.3M in the First Close of its Series B Financing
neuroinflammation, such as pain, Parkinson's disease or ALS. About NeuroTherapia NeuroTherapia is a clinical-stage, privately held biotechnology company developing oral, small-molecule drugs to address neuro-inflammatory conditions of the central nervous system (CNS), including Alzheimer's
More news about: NeuroTherapia, Inc.
Aug 06, 2024, 07:10 ET Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may
More news about: Elevation Oncology
Aug 06, 2024, 07:00 ET Symbiotic Capital, a First-of-its-Kind Life Science Credit Firm, Launches with More than $600 Million Raised
Los Angeles-based investment firm founded by biotechnology entrepreneur Dr. Arie Belldegrun. Symbiotic will structure and originate credit solutions to compelling life science companies to support scientific innovation across biotechnology, medical devices, diagnostics, tools, synthetic biology,
More news about: Symbiotic Capital
Aug 06, 2024, 07:00 ET Apple Tree Partners Launches Red Queen Therapeutics to Bring Potentially Lifesaving Treatments to People at Greatest Risk from Viral Infections
risk. Apple Tree Partners (ATP), a leader in life sciences venture capital, today unveiled Red Queen Therapeutics, a clinical-stage biotechnology company developing novel antiviral treatments for the general population and especially for immunocompromised patients who are at increased risk
More news about: Red Queen Therapeutics
Aug 06, 2024, 07:00 ET Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2
Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may
More news about: Elevation Oncology
Aug 06, 2024, 06:50 ET Bisabolene Market is Forecasted to Reach US$ 4.6 Million by 2034, Expanding at a CAGR of 3.9% | Fact.MR Report
sustainable renewable sources sooner than later. Moreover, microbial methods have become an effective for bisabolene production with the development of biotechnology using genetically engineered bacteria and yeast. North America and East Asia
More news about: Fact.MR
Aug 06, 2024, 06:42 ET Latest Updates of Viva Biotech's Portfolio Companies
On June 27, 2024, Arthrosi Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares
More news about: Viva Biotech Holdings
Aug 06, 2024, 06:30 ET Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner
Strategy and American Pandemic Preparedness Plan, the 2022 U.S. Global Health Security Act, and the President's 2022 Executive Order to Advance Biotechnology and Biomanufacturing Innovation. In this newly created role, Dr. Panjabi will collaborate with Professor the Lord Ara
More news about: Flagship Pioneering
Aug 06, 2024, 06:15 ET Epson Elevates Automation to New Heights with Expanded 6-Axis Robot Lineup
of experience, Epson Robots delivers robots for precision assembly and material handling applications in the aerospace, appliance, automotive, biotechnology, consumer product, electronics, food processing, medical device, pharmaceutical, plastics, semiconductor, and telecommunication industries. For
More news about: Epson America, Inc.
Aug 06, 2024, 05:00 ET First patient enrollment in the U.S. - A milestone for the global multi-center phase Ⅲ clinical trial of telitacicept for myasthenia gravis
RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA:688331), a commercial-stage biotechnology company, announced that the company's self-developed BLyS/APRIL dual targeting fusion protein innovative drug telitacicept has achieved the first
More news about: RemeGen Co., Ltd
Aug 06, 2024, 04:57 ET Regenerative Medicine Market to Reach $531.7 Billion, Globally, by 2033 at 32.4% CAGR: Allied Market Research
contrast, the Asia-Pacific region is poised for rapid growth, driven by increasing healthcare expenditure, expanding biotechnology sectors, and rising awareness of regenerative therapies. Emerging economies in Latin America and the Middle
More news about: Allied Market Research
Aug 05, 2024, 16:03 ET BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance
Conference ID: 1816377 About BioMarin Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root
More news about: BioMarin Pharmaceutical Inc.
Aug 05, 2024, 16:01 ET BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy
ROCTAVIAN® are registered trademarks of BioMarin Pharmaceutical Inc. About BioMarin Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root
More news about: BioMarin Pharmaceutical Inc.
Aug 05, 2024, 10:01 ET Microbiology Culture Market Set for 6.4% CAGR Growth, Driven by Demand from Pharma, Food & Beverage, and Clinical Research Sectors: Transparency Market Research, Inc.
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3232 Felix Biotechnology, a clinical-stage biotherapeutics start-up, is dedicated toward provision of immediate patient care by creation as well as utilization of new
More news about: Transparency Market Research